Less weight or more hype with ▼ rimonabant?

Drug and Therapeutics Bulletin

Volumn 45, Issue 6, 2007, Pages 41-43

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; PLACEBO; RIMONABANT; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; ANTIOBESITY AGENT; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADJUVANT THERAPY; ANXIETY; BEHAVIOR CHANGE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENERGY BALANCE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; INSULIN BLOOD LEVEL; IRRITABILITY; KINESIOTHERAPY; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LOW CALORY DIET; MENTAL DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK REDUCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; CARDIOVASCULAR DISEASE; DRUG EFFECT; RISK FACTOR; TREATMENT OUTCOME;

ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; DRUG COSTS; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 34250643611     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2007.45641     Document Type: Review

References (20)

1. National Institute for Health and Clinical Excellence, 2006. Obesity. Guidance on the prevention, identificaton, assessment and management of overweight and obesity in adults and children [online]. Available: http://guidance.nice.org.uk/CG43/guidance [Accessed 16 May 2007].
2. NHS Health and Social Care Information Centre, 2005. Health Survey for England, 2004 [online]. Available: http://www.ic.nhs.uk/pubs/ hlthsvyeng2004upd [Accessed 16 May 2007].
3. Scottish Executive, 2005. The Scottish Health Survey - 2003. Summary of findings [online]. Available: http:/www.scotland.gov.uk/Resource/ Doc/924/0019811.pdf [Accessed 16 May 2007].
4. Welsh Assembly Government, 2005. Welsh Health Survey 2004/05 [online]. Available: http://new.wales.gov.uk/topics/statistics/ publications/health-survey2004-05/?lang=on [Accessed 16 May 2007].
5. International Obesity TaskForce, 2007. Prevalence of adult obesity [online]. Available: mhtml:http:/www.ioff.org/database/ GlobalPrevalenceofAdultObesityFeb07.mht [Accessed 16 May 2007].
6. Jung RT. Obesity as a disease. Br Med Bull 1997; 53: 307-21.
7. Villamor E, Cnattingius S. Interpregnancy weight change and risk of adverse pregnancy outcomes: a population based study. Lancet 2006; 368: 1164-70.
8. Wilson PW et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162: 1867-72.
9. Fontaine KR et al. Years of life lost due to obesity. JAMA 2003; 289: 187-93.
10. Olshansky SJ et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005; 352: 1138-45.
11. Why and how should adults lose weight? DTB 1998; 36: 89-92.
12. Is ▼silbutramine more than a slim hope? DTB 2001; 39: 89-91.
13. Torgerson JS et al. XENical in the prevention of Diabetes in Obese-Subjects (XENDOS) study: a randomised study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
14. Woods SC. Role of the endocannabinoid system in regulating cadiovascular and metabolic risk factors. Am J Med 2007; 120 (3 suppl 1): S19-25.
15. Acomplia. Summary of product characteristics. France. Sanofi-Aventis, June 2006.
16. Pi-Sunyer FX et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled tiral. JAMA 2006; 295: 761-75.
17. Van Gaal LF et al. Effects of the cannabinoid- 1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97.
18. Despres JP et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-34.
19. Scheen AJ et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-72.
20. Tuthill A et al. Psychiatric co-morbidities in patients attending specialist obesity services in the UK. QJM 2006; 99: 317-25.